• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Immunomedics debuts LeukoScan in Europe

Article

Immunomedics of Morris Plains, NJ, last month began shipments to Germany and Austria of LeukoScan, its radiolabeled monoclonal antibody fragment for the detection of infectious disease.Launches in the U.K. and Ireland are expected by the end of May, with

Immunomedics of Morris Plains, NJ, last month began shipments to Germany and Austria of LeukoScan, its radiolabeled monoclonal antibody fragment for the detection of infectious disease.

Launches in the U.K. and Ireland are expected by the end of May, with deliveries to the rest of the European Union countries to follow by the end of August, according to Philippe Barzin, general manager of the company's European subsidiary in Petten, the Netherlands. Barzin will coordinate sales and marketing for LeukoScan in Europe.

Distribution within the European Union will initially be handled by Mallinckrodt's European affiliate, which also partners with Immunomedics to sell and distribute the company's CEA-Scan colorectal cancer imaging agent.

LeukoScan received final clearance from the European Commission in February for sales and marketing in the 15 E.U. nations. The agent is designed for the detection and diagnosis of osteomyelitis involving long bones, particularly in diabetic patients with foot ulcers, according to the company. Immunomedics filed a biologics license application (BLA) for the product with the Food and Drug Administration in December 1996.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.